EIP Pharma announced on October 6 that a phase 2 study in patients with mild-to-moderate Lewy body dementia (LBD) demonstrated an improvement in cognition as assessed by the Neuropsychological Test Battery (NTB). In the double-blind placebo-controlled study, patients receiving neflamapimod three times daily demonstrated significant improvement on the NTB compared to those who received either placebo or neflamapimod twice daily. In addition, statistically significant improvements or trends were evident on multiple secondary goals.
“The data from the trial of neflamapimod in dementia with Lewy bodies are very encouraging,” said Jeffrey L….